Last 41.25 GBp
Change Today 0.00 / 0.00%
Volume 0.0
PRM On Other Exchanges
As of 11:35 AM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

proteome sciences plc (PRM) Snapshot

41.50 GBp
Previous Close
41.25 GBp
Day High
41.50 GBp
Day Low
41.25 GBp
52 Week High
09/18/13 - 49.00 GBp
52 Week Low
01/7/14 - 27.00 GBp
Market Cap
Average Volume 10 Days
-0.02 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for PROTEOME SCIENCES PLC (PRM)

Related News

No related news articles were found.

proteome sciences plc (PRM) Related Businessweek News

No Related Businessweek News Found

proteome sciences plc (PRM) Details

Proteome Sciences plc, a life sciences company, is engaged in the research and development of biomarkers. The company delivers content for personalized medicine in the areas of biomarker services, biomarker assays, isobaric and isotopic reagents, and proprietary biomarkers. It offers PS Biomarker Services, a biomarker outsourcing solution that provides integrated proteomic services for biomarker discovery, validation, and measurement in clinical trials and in vitro diagnostics. The company develops various proprietary biomarkers for a range of human diseases, including CNS disorders comprising Alzheimer’s, Huntington’s, stroke, traumatic brain injury, TSE’s, and pain; oncology consisting of lung, breast, esophageal, colorectal cancers, and neuroblastoma; and organ transplant rejection, such as renal and cardiac diseases. In addition, it offers protein tags and assays for spectrometry analysis; develops isobaric and isotopic reagents under the Tandem Mass Tag brand; and provides Sensitizer tags for the labeling of proteins and peptides. Further, the company’s biomarker services include proteomics, peptidomics, sample preparation, profiling, identification, and validation services. It serves pharmaceutical and biotechnology companies, and academia clients in the United Kingdom, Germany, and the United States. Proteome Sciences plc is headquartered in Cobham, the United Kingdom.

33 Employees
Last Reported Date: 06/9/14

proteome sciences plc (PRM) Top Compensated Officers

Executive Chairman
Total Annual Compensation: 376.5K GBP
Finance Director, Secretary and Executive Dir...
Total Annual Compensation: 246.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 210.0K GBP
Compensation as of Fiscal Year 2013.

proteome sciences plc (PRM) Key Developments

Proteome Sciences Announces Publication of Alzheimer's Blood Test Study

Proteome Sciences announced publication of a study it has co-authored with King's College London in which a set of 10 proteins in the blood have been identified which can predict the onset of Alzheimer's disease. The study which analysed over 1,000 individuals is the larger of its kind to date and marks a significant step towards developing a blood test for the disease. There are currently no effective long-lasting drug treatments for Alzheimer's, and it is believed that many new clinical trials fail because drugs are given too late in the disease process. A blood test could be used to identify patients in the early stages of memory loss for clinical trials to find drugs to halt the progression of the disease. The study is the result of an international collaboration led by King's College London and Proteome Sciences plc, funded by Alzheimer's Research UK, the UK Medical Research Council, the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre and Proteome Sciences. The researchers used data from three international studies. Blood samples from a total of 1,148 individuals (476 with Alzheimer's disease; 220 with 'Mild Cognitive Impairment' (MCI) and 452 elderly controls without dementia) were analysed for 26 proteins previously shown to be associated with Alzheimer's disease. A sub-group of 476 individuals across all three groups also had an MRI brain scan. Researchers identified 16 of these 26 proteins to be strongly associated with brain shrinkage in either MCI or Alzheimer's. They then ran a second series of tests to establish which of these proteins could predict the progression from MCI to Alzheimer's. They identified a combination of 10 proteins capable of predicting whether individuals with MCI would develop Alzheimer's disease within a year, with an accuracy of 87%.

Proteome Sciences plc Announces Management Changes

Proteome Sciences announced the appointment of Roger Steven McDowell to the Board of the company as a non-executive Director with immediate effect. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director. The CEO, Christopher Pearce, has been appointed Executive Chairman.

Proteome Sciences PLC Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2013

Proteome Sciences PLC reported unaudited consolidated earnings results for the year ended December 31, 2013. For the period, the company reported £2,136,681 against £1,152,967 a year ago. Operating loss was £3,372,515 against £4,240,994 a year ago. Operating loss was £3,372,515 against £4,240,994 a year ago. Loss before taxation was £3,596,188 against £5,195,487,000 a year ago. Loss for the period from continuing operations attributed to shareholders of the company was £3,149,159 or 1.62 pence per basic and diluted share against £4,253,594,000 or 2.21 pence per basic and diluted share a year ago. Net cash outflow from operating activities was £2,766,987 against £3,353,367,000 a year ago. Purchases of property, plant and equipment were £9,202 against £14,603,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRM:LN 41.25 GBp 0.00

PRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTEOME SCIENCES PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at